Coleman RL et al. VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC). ESMO 2019;Abstract LBA3.
Colombo PE et al. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit Rev Oncol Hematol 2014;89(2):207-16. Abstract
Fuh K et al. Homologous recombination deficiency real-time clinical assays, ready or not? Gynecol Oncol 2020;159(3):877-86. Abstract
Gonzalez-Martin A et al. Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study). ESMO 2019;Abstract LBA1.
Gonzalez-Martin A et al. A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: Blinded pooled interim safety data from the PRIMA Study. ESMO 2018;Abstract 941PD.
Izar B et al. A single-cell landscape of high-grade serous ovarian cancer. Nat Med 2020;26(8):1271-9. Abstract
Konstantinopoulos PA et al. TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC) — Results from ROC cohort. ASCO 2018;Abstract 106.
Lee EK, Matulonis UA. PARP inhibitor resistance mechanisms and implications for post-progression combination therapies. Cancers (Basel) 2020;12(8):2054. Abstract
Lynce F, Isaacs C. How far do we go with genetic evaluation? Gene, panel, and tumor testing. ASCO Educational Book 2016;35:e72-8. Abstract
Moore K et al. Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC). ESMO 2020;Abstract LBA31.
Moore K et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379(26):2495-505. Abstract
Nitecki R et al. The incidence of myelodysplastic syndrome in patients receiving poly-ADP ribose polymerase inhibitors for treatment of solid tumors: A meta-analysis. ASCO 2020;Abstract 3641.
Ray-Coquard I et al. Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. ESMO 2019;Abstract LBA2_PR.
Tew WP et al. PARP inhibitors in the management of ovarian cancer: ASCO Guideline. J Clin Oncol 2020;38(30):3468-93. Abstract